| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, and 2 Departments of Medicine and Genome Sciences, University of Washington, Seattle, Washington
Neoplastic progression is an evolutionary process characterized by genomic instability and waves of clonal expansions carrying genetic and epigenetic lesions to fixation (100% of the cell population). However, an evolutionarily neutral lesion may also reach fixation if it spreads as a hitchhiker on a selective sweep. We sought to distinguish advantageous lesions from hitchhikers in the premalignant condition Barrett’s esophagus. Patients (211) had biopsies taken at 2-cm intervals in their Barrett’s segments. Purified epithelial cells were assayed for loss of heterozygosity and microsatellite shifts on chromosomes 9 and 17, sequence mutations in CDKN2A/MTS1/INK4a (p16) and TP53 (p53), and methylation of the p16 promoter. We measured the expanse of a lesion in a Barrett’s segment as the proportion of proliferating cells that carried a lesion in that locus. We then selected the lesion having expanses >90% in the greatest number of patients as our first putative advantageous lesion. We filtered out hitchhikers by removing all expanses of other lesions that did not occur independent of the advantageous lesion. The entire process was repeated on the remaining expanses to identify additional advantageous lesions. p16 loss of heterozygosity, promoter methylation, and sequence mutations have strong, independent, advantageous effects on Barrett’s cells early in progression. Second lesions in p16 and p53 are associated with later selective sweeps. Virtually all of the other lesion expansions, including microsatellite shifts, could be explained as hitchhikers on p16 lesion clonal expansions. These techniques can be applied to any neoplasm.
This article has been cited by other articles:
|
|
 |
|
  B. J. Reid Cancer Risk Assessment and Cancer Prevention: Promises and Challenges Cancer Prevention Research, September 1, 2008; 1(4): 229 - 232. [Full Text] [PDF]
|
|
|
|
 |
|
 R. C Fitzgerald Dissecting out the genetic origins of Barrett's oesophagus Gut, August 1, 2008; 57(8): 1033 - 1034. [Full Text] [PDF]
|
|
|
|
|
|
S J Leedham, S L Preston, S A C McDonald, G Elia, P Bhandari, D Poller, R Harrison, M R Novelli, J A Jankowski, and N A Wright Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus Gut, August 1, 2008; 57(8): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S J Leedham and N A Wright Expansion of a mutated clone: from stem cell to tumour J. Clin. Pathol., February 1, 2008; 61(2): 164 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lao-Sirieix, L. Lovat, and R. C. Fitzgerald Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance Clin. Cancer Res., January 15, 2007; 13(2): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Kuhner Robustness of Coalescent Estimators to Between-Lineage Mutation Rate Variation Mol. Biol. Evol., December 1, 2006; 23(12): 2355 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, C. R. Pickering, C. R. Holst, M. L. Gauthier, and T. D. Tlsty p16INK4a Modulates p53 in Primary Human Mammary Epithelial Cells Cancer Res., November 1, 2006; 66(21): 10325 - 10331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R D Odze Diagnosis and grading of dysplasia in Barrett's oesophagus. J. Clin. Pathol., October 1, 2006; 59(10): 1029 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Keswani, A. Noffsinger, I. Waxman, and M. Bissonnette Clinical Use of p53 in Barrett's Esophagus. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1243 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Maley, P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, P. L. Blount, and B. J. Reid The Combination of Genetic Instability and Clonal Expansion Predicts Progression to Esophageal Adenocarcinoma Cancer Res., October 15, 2004; 64(20): 7629 - 7633. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
